Regulation of intestinal cytochrome p450 expression by hepatic cytochrome p450: Possible involvement of fibroblast growth factor 15 and impact on systemic drug exposure

Yi Zhu, Xinxin Ding, Cheng Fang, Qing Yu Zhang

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Tissue-specific deletion of the gene for NADPH-cytochrome P450 (P450) reductase (CPR), the essential electron donor to all microsomal P450 enzymes, in either liver or intestine, leads to upregulation of many P450 genes in the tissue with the Cpr deletion. Here, by studying the liver-specific Cpr-null (LCN) mouse, we examined whether an interorgan regulatory pathway exists, such that a loss of hepatic CPR would cause compensatory changes in intestinal P450 expression and capacity for first-pass metabolism of oral drugs. We show for the first time that intestinal expression of CYP2B, 2C, and 3A proteins was increased in LCN mice by 2- to 3-fold compared with wild-type (WT) mice, accompanied by significant increases in small intestinal microsomal lovastatin-hydroxylase activity and systemic clearance of oral lovastatin (at 5 mg/kg). Additional studies showed that the hepatic Cpr deletion, which caused large decreases in bile acid (BA) levels in the liver, intestine, plasma, and intestinal content, led to drastic decreases in the mRNA levels of intestinal fibroblast growth factor 15 (FGF15), a target gene of the BA receptor farnesoid X receptor. Furthermore, treatment of mice with FGF19 (the human counterpart of mouse FGF15) abolished the difference between WT and LCN mice in small intestinal (SI) CYP3A levels at 6 hours after the treatment. Our findings reveal a previously unrecognized direct role of intestinal FGF15/19 in the regulation of SI P450 expression and may have profound implications for the prediction of drug exposure in patients with compromised hepatic P450 function.

Original languageEnglish (US)
Pages (from-to)139-147
Number of pages9
JournalMolecular pharmacology
Volume85
Issue number1
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Fibroblast Growth Factors
Cytochrome P-450 Enzyme System
Liver
Pharmaceutical Preparations
Lovastatin
Cardiopulmonary Resuscitation
Bile Acids and Salts
Intestines
Cytochrome P-450 CYP3A
Gastrointestinal Contents
Gene Deletion
Mixed Function Oxygenases
NADP
Genes
Oxidoreductases
Up-Regulation
Tissue Donors
Electrons
Messenger RNA
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Regulation of intestinal cytochrome p450 expression by hepatic cytochrome p450 : Possible involvement of fibroblast growth factor 15 and impact on systemic drug exposure. / Zhu, Yi; Ding, Xinxin; Fang, Cheng; Zhang, Qing Yu.

In: Molecular pharmacology, Vol. 85, No. 1, 01.01.2014, p. 139-147.

Research output: Contribution to journalArticle

@article{a188c6f8a16448b69841f0831e4edf5d,
title = "Regulation of intestinal cytochrome p450 expression by hepatic cytochrome p450: Possible involvement of fibroblast growth factor 15 and impact on systemic drug exposure",
abstract = "Tissue-specific deletion of the gene for NADPH-cytochrome P450 (P450) reductase (CPR), the essential electron donor to all microsomal P450 enzymes, in either liver or intestine, leads to upregulation of many P450 genes in the tissue with the Cpr deletion. Here, by studying the liver-specific Cpr-null (LCN) mouse, we examined whether an interorgan regulatory pathway exists, such that a loss of hepatic CPR would cause compensatory changes in intestinal P450 expression and capacity for first-pass metabolism of oral drugs. We show for the first time that intestinal expression of CYP2B, 2C, and 3A proteins was increased in LCN mice by 2- to 3-fold compared with wild-type (WT) mice, accompanied by significant increases in small intestinal microsomal lovastatin-hydroxylase activity and systemic clearance of oral lovastatin (at 5 mg/kg). Additional studies showed that the hepatic Cpr deletion, which caused large decreases in bile acid (BA) levels in the liver, intestine, plasma, and intestinal content, led to drastic decreases in the mRNA levels of intestinal fibroblast growth factor 15 (FGF15), a target gene of the BA receptor farnesoid X receptor. Furthermore, treatment of mice with FGF19 (the human counterpart of mouse FGF15) abolished the difference between WT and LCN mice in small intestinal (SI) CYP3A levels at 6 hours after the treatment. Our findings reveal a previously unrecognized direct role of intestinal FGF15/19 in the regulation of SI P450 expression and may have profound implications for the prediction of drug exposure in patients with compromised hepatic P450 function.",
author = "Yi Zhu and Xinxin Ding and Cheng Fang and Zhang, {Qing Yu}",
year = "2014",
month = "1",
day = "1",
doi = "10.1124/mol.113.088914",
language = "English (US)",
volume = "85",
pages = "139--147",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Regulation of intestinal cytochrome p450 expression by hepatic cytochrome p450

T2 - Possible involvement of fibroblast growth factor 15 and impact on systemic drug exposure

AU - Zhu, Yi

AU - Ding, Xinxin

AU - Fang, Cheng

AU - Zhang, Qing Yu

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Tissue-specific deletion of the gene for NADPH-cytochrome P450 (P450) reductase (CPR), the essential electron donor to all microsomal P450 enzymes, in either liver or intestine, leads to upregulation of many P450 genes in the tissue with the Cpr deletion. Here, by studying the liver-specific Cpr-null (LCN) mouse, we examined whether an interorgan regulatory pathway exists, such that a loss of hepatic CPR would cause compensatory changes in intestinal P450 expression and capacity for first-pass metabolism of oral drugs. We show for the first time that intestinal expression of CYP2B, 2C, and 3A proteins was increased in LCN mice by 2- to 3-fold compared with wild-type (WT) mice, accompanied by significant increases in small intestinal microsomal lovastatin-hydroxylase activity and systemic clearance of oral lovastatin (at 5 mg/kg). Additional studies showed that the hepatic Cpr deletion, which caused large decreases in bile acid (BA) levels in the liver, intestine, plasma, and intestinal content, led to drastic decreases in the mRNA levels of intestinal fibroblast growth factor 15 (FGF15), a target gene of the BA receptor farnesoid X receptor. Furthermore, treatment of mice with FGF19 (the human counterpart of mouse FGF15) abolished the difference between WT and LCN mice in small intestinal (SI) CYP3A levels at 6 hours after the treatment. Our findings reveal a previously unrecognized direct role of intestinal FGF15/19 in the regulation of SI P450 expression and may have profound implications for the prediction of drug exposure in patients with compromised hepatic P450 function.

AB - Tissue-specific deletion of the gene for NADPH-cytochrome P450 (P450) reductase (CPR), the essential electron donor to all microsomal P450 enzymes, in either liver or intestine, leads to upregulation of many P450 genes in the tissue with the Cpr deletion. Here, by studying the liver-specific Cpr-null (LCN) mouse, we examined whether an interorgan regulatory pathway exists, such that a loss of hepatic CPR would cause compensatory changes in intestinal P450 expression and capacity for first-pass metabolism of oral drugs. We show for the first time that intestinal expression of CYP2B, 2C, and 3A proteins was increased in LCN mice by 2- to 3-fold compared with wild-type (WT) mice, accompanied by significant increases in small intestinal microsomal lovastatin-hydroxylase activity and systemic clearance of oral lovastatin (at 5 mg/kg). Additional studies showed that the hepatic Cpr deletion, which caused large decreases in bile acid (BA) levels in the liver, intestine, plasma, and intestinal content, led to drastic decreases in the mRNA levels of intestinal fibroblast growth factor 15 (FGF15), a target gene of the BA receptor farnesoid X receptor. Furthermore, treatment of mice with FGF19 (the human counterpart of mouse FGF15) abolished the difference between WT and LCN mice in small intestinal (SI) CYP3A levels at 6 hours after the treatment. Our findings reveal a previously unrecognized direct role of intestinal FGF15/19 in the regulation of SI P450 expression and may have profound implications for the prediction of drug exposure in patients with compromised hepatic P450 function.

UR - http://www.scopus.com/inward/record.url?scp=84890671843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890671843&partnerID=8YFLogxK

U2 - 10.1124/mol.113.088914

DO - 10.1124/mol.113.088914

M3 - Article

AN - SCOPUS:84890671843

VL - 85

SP - 139

EP - 147

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 1

ER -